Bullish Case: DOLE at $12.725 sits near the lower end of its multi-year range, and Helium's density function concentrates mass at $12.5 (0.41 density) with meaningful weight at $15 (0.29), implying upside asymmetry toward the mid-teens. The Feb 2027 12.5C at 32.5 IV vs. a 26.1 IV 12.5P shows modest call-side normalization, defensive staples demand persists, and any margin stabilization or buyback execution could re-rate shares to $14-$15 as the negative momentum (flat recent action, -1.4% week) exhausts.

Bearish Case: The term structure remains in backwardation and short-dated deep-put IV (10/16 10P at 95.7%, 7.5P at 244%) still prices severe left-tail risk. Price is down 7.5% in a month and -20.5% over two years, the historical return surface carries non-trivial mass in negative regimes for longer holds, and the market-implied density (0.21 at $7.50) assigns far more crash weight than Helium's model. Fruit-cost deflation, supply gluts, or an idiosyncratic shock could drive $11 or lower.

Potential Outcomes:

1. 35% Rangebound $12-$14 through Q4 — momentum flat, Helium density peaks at $12.5; falsified if closes < $12 or > $14.50 for 3 weeks.
2. 25% Rebound to $14-$15 by Feb 2027 — Feb 12.5C delta 0.60 and call IV (32.5%) below put IV suggest recovery priced; falsified if put IV keeps rising.
3. 20% Slide to $11-$12 — backwardation + -7.5% monthly drift persists; falsified by rapid deep-put IV compression.
4. 12% Overshoot to $15-$17 — earnings/margin beat plus squeeze; falsified if spot stalls < $13.50 into Nov 20 expiry.
5. 8% Crash < $10 — market density at $7.50 (0.21) flags tail; falsified if 7.5P IV collapses.

Oracle: defined-risk call spreads only above $13 confirmation; hedge via Nov 10P if skew steepens further.

October 01, 2026